PL EN


Preferences help
enabled [disable] Abstract
Number of results
2020 | 3 | 1 | 60-65
Article title

The role of interdisciplinary cooperation in the prevention of medication-related osteonecrosis of the jaw (MRONJ)

Content
Title variants
Languages of publication
EN
Abstracts
EN
Medication-related osteonecrosis of the jaw (MRONJ) is considered one of the most severe complications of treatment with antiresorptive drugs. The number of patients with MRONJ has significantly increased due to the broadening of the indication to treat with bisphosphonates and other antiresorptive drugs (e.g. denosumab). Because MRONJ has a significant impact on the patients’ quality of life, it is necessary to reduce the risk of such complications by implementing preventive measures, e.g. full dental and oral cavity examination for all patients qualified for treatment with angiogenesis inhibitors or antiresorptive drugs.
Keywords
Year
Volume
3
Issue
1
Pages
60-65
Physical description
Dates
published
2020-05-29
received
2020-03-25
accepted
2020-04-15
Contributors
References
  • Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg [Internet]. 2003 Sep;61(9):1115–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0278239103007201.
  • Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg [Internet]. 2004 May;62(5):527–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0278239104001958.
  • Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-2009 Update. J Oral Maxillofac Surg [Internet]. 2009 May;67(5):2–12. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0278239109001153.
  • Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw – 2014 Update. J Oral Maxillofac Surg [Internet]. 2014 Oct;72(10):1938–56. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0278239114004637.
  • Muthukrishnan A, Bijai Kumar L, Ramalingam G. Medication-related osteonecrosis of the jaw: a dentist’s nightmare. BMJ Case Rep [Internet]. 2016 Apr 6;2016:bcr2016214626. Available from: http://casereports.bmj.com/lookup/doi/10.1136/bcr-2016-214626.
  • Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. 2019 Feb;127(2):117–35. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2212440318311933.
  • Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int [Internet]. 2018 Sep 16;2018:1–10. Available from: https://www.hindawi.com/journals/bmri/2018/2684924/.
  • Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral y Cir Bucal [Internet]. 2020;25(1):e71–83. Available from: http://www.medicinaoral.com/medoralfree01/aop/23191.pdf.
  • Dunphy L, Salzano G, Gerber B, Graystone J. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Rep [Internet]. 2020 Jan 5;13(1):e224455. Available from: http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-224455.
  • Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev [Internet]. 2017 Oct 6; Available from: http://doi.wiley.com/10.1002/14651858.CD012432.pub2.
  • McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis [Internet]. 2018 May;24(4):527–36. Available from: http://doi.wiley.com/10.1111/odi.12708.
  • Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging [Internet]. 2018 Feb 12;35(2):163–73. Available from: http://link.springer.com/10.1007/s40266-018-0525-7.
  • Mander K, Finnie J. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Aust Vet J [Internet]. 2018 Oct;96(10):371–8. Available from: http://doi.wiley.com/10.1111/avj.12747.
  • Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev [Internet]. 2018 Sep;69(February):177–87. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0305737218301014.
  • Jacobsen C, Zemann W, Obwegeser JA, Grätz KW, Metzler P. The phosphorous necrosis of the jaws and what can we learn from the past: a comparison of “phossy” and “bisphossy” jaw. Oral Maxillofac Surg [Internet]. 2014 Mar 28;18(1):31–7. Available from: http://link.springer.com/10.1007/s10006-012-0376-z.
  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. J Bone Miner Res [Internet]. 2015 Jan;30(1):3–23. Available from: http://doi.wiley.com/10.1002/jbmr.2405.
  • Göllner M, Holst S, Fenner M, Schmitt J. Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: A clinical report. J Prosthet Dent [Internet]. 2010 Apr;103(4):196–201. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022391310000521.
  • Hasegawa Y, Kawabe M, Kimura H, Kurita K, Fukuta J, Urade M. Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related osteonecrosis of the jaws: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. 2012 Sep;114(3):318–24. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2212440312003136.
  • Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Futur Oncol [Internet]. 2014 Feb;10(2):257–75. Available from: https://www.futuremedicine.com/doi/10.2217/fon.13.211.
  • Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol [Internet]. 2019 Sep 1;37(25):2270–90. Available from: http://ascopubs.org/doi/10.1200/JCO.19.01186.
  • Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab [Internet]. 2017 Jan 29;35(1):6–19. Available from: http://link.springer.com/10.1007/s00774-016-0810-7.
  • Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. J Am Dent Assoc [Internet]. 2011 Nov;142(11):1243–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002817714628142.
  • Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent [Internet]. 2016;6(2):97. Available from: http://www.jispcd.org/text.asp?2016/6/2/97/178742.
  • Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol [Internet]. 2014 Sep;25:iii124–37. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419340785.
  • Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S. Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin [Internet]. 2016 Jul 2;32(7):1261–8. Available from: http://www.tandfonline.com/doi/full/10.1185/03007995.2016.1170005
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.doi-10_31373_ejtcm_120581
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.